Patents by Inventor Albert Jeans

Albert Jeans has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240150393
    Abstract: Provided herein is a compound of Formula (I-I) or a pharmaceutically acceptable salt thereof, wherein the variables are defined herein. Also provided herein are pharmaceutical compositions comprising a compound of Formula (I-I), and methods of using the compounds, e.g., in the treatment of CNS-related disorders.
    Type: Application
    Filed: June 5, 2023
    Publication date: May 9, 2024
    Inventors: Albert Jean Robichaud, Francesco G. Salituro, Maria Jesus Blanco-Pillado, Daniel La, Boyd L. Harrison
  • Publication number: 20240148136
    Abstract: A kit is provided that, when assembled, forms a unit of furniture. The kit includes side panels that can reversibly slide into an opening formed in the sides of the front and side panels. The kit may include multiple locking pins and cleats to restrict movement of the top and side panels. The kit may include positioning wedges and/or locking wedges to restrict relative movement of the panels and thus improve the stability of the unit. Also provided are methods of assembling the unit of furniture.
    Type: Application
    Filed: January 16, 2024
    Publication date: May 9, 2024
    Applicant: Crawford & Burke Company Limited
    Inventors: Albert Jean DeSmet, Justin Albert DeSmet
  • Patent number: 11970485
    Abstract: Disclosed herein are compounds of formula I: or a pharmaceutically acceptable salt thereof, where the variables are as defined herein. These compounds are useful in treating RET associated cancers. Formulations containing the compounds of formula I and methods of making the compounds of formula I are also disclosed.
    Type: Grant
    Filed: October 19, 2022
    Date of Patent: April 30, 2024
    Assignee: ELI LILLY AND COMPANY
    Inventors: Gabrielle R. Kolakowski, Erin D. Anderson, Steven W. Andrews, Christopher Pierre Albert Jean Boldron, Kevin R. Condroski, Thomas C. Irvin, Manoj Kumar, Elizabeth A. McFaddin, Megan L. McKenney, Johnathan Alexander McLean, Tiphaine Mouret, Michael J. Munchhof, Thomas Pierre Dino Pancaldi, Michael Alexander Pilkington-Miksa, Marta Pinto
  • Publication number: 20240132535
    Abstract: Compounds are provided according to Formula (I) and pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof; wherein R1, R2, and R3 are as defined herein. Compounds of the present invention are contemplated useful for the prevention and treatment of a variety of conditions.
    Type: Application
    Filed: June 29, 2023
    Publication date: April 25, 2024
    Inventors: Francesco G. Salituro, Albert Jean Robichaud, Gabriel Martinez Botella, Boyd L. Harrison
  • Patent number: 11945836
    Abstract: Described herein are neuroactive steroids of the Formula (II): or a pharmaceutically acceptable salt thereof; wherein A, R1, R2a, R2b, R3a, R3b, R4a, R4b, R5, R6 and are as defined herein. Such compounds are envisioned, in certain embodiments, to behave as GABA modulators. The present invention also provides pharmaceutical compositions comprising a compound of the present invention and methods of use and treatment, e.g., such for inducing sedation and/or anesthesia.
    Type: Grant
    Filed: October 4, 2022
    Date of Patent: April 2, 2024
    Assignee: Sage Therapeutics, Inc.
    Inventors: Gabriel Martinez Botella, Boyd L. Harrison, Albert Jean Robichaud, Francesco G. Salituro, Richard Thomas Beresis
  • Publication number: 20240092824
    Abstract: Provided herein is a compound of Formula (I) or a pharmaceutically acceptable salt thereof, wherein R3a, R5, R6a, R6b, R17, R21a, R21b, Rm, Rn, R16a, R16b, R7a, R7b, R12a, R12b, R11a, R11b, R2a, R2b, R19, R4a, and R4b are defined herein. Also provided herein are pharmaceutical compositions comprising a compound of Formula (I) and methods of using the compounds, e.g., in the treatment of CNS-related disorders.
    Type: Application
    Filed: April 24, 2023
    Publication date: March 21, 2024
    Inventors: Francesco G. Salituro, Albert Jean Robichaud
  • Patent number: 11936838
    Abstract: A method is described for rendering a spatial part of an immersive video on a display of a client device comprising a tile frame retrieval device, a decoder device and a renderer device, wherein the immersive video comprises video frames, each video frame being spatially divided in tile frames, and the immersive video comprises tile streams, each tile stream representing a spatial part of the immersive video and each tile stream comprising a plurality of said tile frames, and wherein the client has stored tile stream mapping information, that indicates for each tile stream a respective position on a surface of a two-dimensional or three-dimensional model, such as a sphere or cube, the method comprising based on said tile stream mapping information and a viewport, the tile frame retrieval device determining a plurality of tile streams, and requesting encoded video data from a server, the encoded video data comprising, for each determined tile stream, an encoded tile frame that comprises encoded data representa
    Type: Grant
    Filed: July 3, 2020
    Date of Patent: March 19, 2024
    Assignee: TILEDMEDIA B.V.
    Inventors: Ray Van Brandenburg, Xavier Albert Jean-Pierre Corbillon, Arjen Timotheus Veenhuizen
  • Patent number: 11926646
    Abstract: Compounds are provided according to Formula (A): and pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof; wherein R1A, R1B, n, R2A, R2B, R3, and R4 are as defined herein. Compounds of the present invention are contemplated useful for the prevention and treatment of a variety of conditions.
    Type: Grant
    Filed: September 15, 2021
    Date of Patent: March 12, 2024
    Assignee: Sage Therapeutics, Inc.
    Inventors: Francesco G. Salituro, Albert Jean Robichaud, Gabriel Martinez Botella, Andrew Griffin, Boyd L. Harrison, Daniel La
  • Publication number: 20240076310
    Abstract: Provided herein are 19-nor C3, 3-disubstituted steroids of Formula (I): and pharmaceutically acceptable salts thereof; wherein R1, R2, R3, and R4 are as defined herein, and A is a heteroaryl ring system comprising 3 or 4 nitrogens as defined herein. Such compounds are contemplated useful for the prevention and treatment of a variety of CNS-related conditions, for example, treatment of sleep disorders, mood disorders, schizophrenia spectrum disorders, convulsive disorders, disorders of memory and/or cognition, movement disorders, personality disorders, autism spectrum disorders, pain, traumatic brain injury, vascular diseases, substance abuse disorders and/or withdrawal syndromes, and tinnitus.
    Type: Application
    Filed: October 6, 2023
    Publication date: March 7, 2024
    Inventors: Gabriel Martinez Botella, Boyd L. Harrison, Albert Jean Robichaud, Francesco G. Salituro, Richard Thomas Beresis
  • Patent number: 11912737
    Abstract: Provided herein are 3,3-disubstituted 19-nor-steroidal compounds according to Formula (I): and pharmaceutical compositions thereof. Such compounds are contemplated useful for the prevention and treatment of a variety of CNS-related conditions, for example, treatment of sleep disorders, mood disorders, schizophrenia spectrum disorders, disorders of memory and/or cognition, movement disorders, personality disorders, autism spectrum disorders, pain, traumatic brain injury, vascular diseases, substance abuse disorders and/or withdrawal syndromes, tinnitus, status epilepticus.
    Type: Grant
    Filed: October 9, 2020
    Date of Patent: February 27, 2024
    Assignee: Sage Therpeutics, Inc.
    Inventors: Gabriel Martinez Botella, Boyd L. Harrison, Albert Jean Robichaud, Francesco G. Salituro, Richard Thomas Beresis
  • Patent number: 11905309
    Abstract: 3beta, 17beta disubstituted steroidal compounds, pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, are provided for the prevention and treatment of a variety of CNS-related conditions.
    Type: Grant
    Filed: July 21, 2021
    Date of Patent: February 20, 2024
    Assignee: SAGE THERAPEUTICS, INC.
    Inventors: Gabriel Martinez Botella, Boyd L Harrison, Albert Jean Robichaud, Francesco G. Salituro
  • Patent number: 11884697
    Abstract: Compounds are provided according to Formula (I), and pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof; wherein A, R1, and R5 are as defined herein. Compounds of the present invention are contemplated useful for the prevention and treatment of a variety of conditions.
    Type: Grant
    Filed: April 28, 2021
    Date of Patent: January 30, 2024
    Assignee: Sage Therapeutics, Inc.
    Inventors: Albert Jean Robichaud, Francesco G. Salituro, Gabriel Martinez Botella, Boyd L. Harrison, John Gregory Reid
  • Publication number: 20240025942
    Abstract: Described herein are neuroactive steroids of the Formula (I): or a pharmaceutically acceptable salt thereof; wherein R1, R2, Ra G, X, Y, Z, and n are as defined herein. Such compounds are envisioned, in certain embodiments, to behave as GABA modulators. Also provided are pharmaceutical compositions comprising a compound described herein and methods of use and treatment, e.g., such for inducing sedation and/or anesthesia.
    Type: Application
    Filed: July 10, 2023
    Publication date: January 25, 2024
    Inventors: Albert Jean Robichaud, Francesco G. Salituro, Boyd L. Harrison, Gabriel Martinez Botella
  • Patent number: 11878995
    Abstract: Compounds are provided according to Formula (III): and pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof; wherein R2, R3, R5, and n are as defined herein, and at least one hydrogen is replaced with a deuterium. Compounds of the present invention are contemplated useful for the prevention and treatment of a variety of conditions.
    Type: Grant
    Filed: July 8, 2022
    Date of Patent: January 23, 2024
    Assignee: Sage Therapeutics, Inc.
    Inventors: Gabriel Martinez Botella, Boyd L Harrison, Albert Jean Robichaud, Francesco G. Salituro
  • Patent number: 11851457
    Abstract: Compounds are provided according to Formula (I): and pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof; wherein R2, R3, R4, R5, and R6 are as defined herein. Compounds of the present invention are contemplated useful for the prevention and treatment of a variety of conditions.
    Type: Grant
    Filed: August 5, 2021
    Date of Patent: December 26, 2023
    Assignee: SAGE THERAPEUTICS
    Inventors: Francesco G. Salituro, Albert Jean Robichaud, Gabriel Martinez Botella, Boyd L. Harrison, Andrew Griffin
  • Publication number: 20230391816
    Abstract: Described herein are steroids of Formula (I): and pharmaceutically acceptable salts thereof, wherein R1, R2a, R2b, R3, R4, R5a, R5b, R6, and Z are as defined herein. Such compounds are contemplated useful for the prevention and treatment of a variety of CNS-related conditions, for example, treatment of sleep disorders, mood disorders, schizophrenia spectrum disorders, convulsive disorders, disorders of memory and/or cognition, movement disorders, personality disorders, autism spectrum disorders, pain, traumatic brain injury, vascular diseases, substance abuse disorders and/or withdrawal syndromes, and tinnitus.
    Type: Application
    Filed: August 24, 2023
    Publication date: December 7, 2023
    Inventors: Boyd L. Harrison, Gabriel Martinez Botella, Albert Jean Robichaud, Francesco G. Salituro
  • Publication number: 20230348526
    Abstract: Compounds are provided according to Formula (I) and pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, wherein X, Y, R1, R2a, R2b, R4a, R4b, R5a, R5b, R6a, R6b, R7, and R8 are as defined herein. Compounds of the present invention are contemplated useful for the prevention and treatment of a variety of conditions.
    Type: Application
    Filed: March 2, 2023
    Publication date: November 2, 2023
    Inventors: Boyd L. Harrison, Gabriel Martinez Botella, Albert Jean Robichaud, Francesco G. Salituro
  • Publication number: 20230331768
    Abstract: Compounds are provided according to Formula (A): and pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof; wherein R1, R2, R3? R4, R5, R6, and RG are as defined herein. Compounds of the present invention are contemplated useful for the prevention and treatment of a variety of conditions.
    Type: Application
    Filed: February 6, 2023
    Publication date: October 19, 2023
    Inventors: Francesco G. Salituro, Albert Jean Robichaud, Gabriel Martinez Botella, Boyd L. Harrison, Andrew Griffin
  • Patent number: 11780875
    Abstract: Described herein are steroids of Formula (I): and pharmaceutically acceptable salts thereof; wherein R1, R2a, R2b, R3, R4, R5a, R5b, R6, and Z are as defined herein. Such compounds are contemplated useful for the prevention and treatment of a variety of CNS-related conditions, for example, treatment of sleep disorders, mood disorders, schizophrenia spectrum disorders, convulsive disorders, disorders of memory and/or cognition, movement disorders, personality disorders, autism spectrum disorders, pain, traumatic brain injury, vascular diseases, substance abuse disorders and/or withdrawal syndromes, and tinnitus.
    Type: Grant
    Filed: September 13, 2021
    Date of Patent: October 10, 2023
    Assignee: Sage Therapeutics, Inc.
    Inventors: Boyd L. Harrison, Gabriel Martinez Botella, Albert Jean Robichaud, Francesco G. Salituro
  • Publication number: 20230287037
    Abstract: Provided herein are 3,3-disubstituted 19-nor-steroidal compounds according to Formula (I) and (III): where R1, R2, R3, R3?, R4, R6a, R6a, R11a, and R11b are as defined herein. Compounds of the present invention are contemplated useful for the prevention and treatment of a variety of CNS-related conditions, for example, treatment of sleep disorders, mood disorders, insomnia, anxiety, depression, traumatic brain injury (TBI), stress, and epilepsy.
    Type: Application
    Filed: October 19, 2022
    Publication date: September 14, 2023
    Inventors: Ravindra B. Upasani, Benny C. Askew, JR., Boyd L. Harrison, Francesco G. Salituro, Albert Jean Robichaud